Full Breakdown
Daraxonrasib Shows Promise as First KRAS Inhibitor to Extend Survival in Pancreatic Cancer
5/30/2026, 4:28:51 AM
Survival Gains in Early Daraxonrasib Trial
In a Phase 1/2 study of 168 patients with pancreatic ductal adenocarcinoma, daraxonrasib yielded overall survival of 13.2 months versus 6.7 months with standard chemotherapy. Progression-free survival was 8.5 months. Among 26 patients with the KRAS G12 mutation, one-third had an objective response (>=30 % tumor shrinkage).
Targeting KRAS: From ‘Undruggable’ to Inhibitor
KRAS mutations drive >90 % of pancreatic cancers but have been deemed “undruggable” due to a smooth intracellular surface and few binding pockets. A 2013 discovery of a hidden pocket enabled molecules to bind KRAS intracellularly. Daraxonrasib belongs to a new class that engages multiple KRAS mutant forms, eliminating mutation-specific testing.
Safety Profile
Severe adverse events occurred in ~30 % of participants; rash was reported in 90 % and about half experienced diarrhea, oral or gastrointestinal inflammation, nausea, vomiting or fatigue. The toxicity was described as “manageable” compared with conventional chemotherapy.
Official Statements & Regulatory Status
The FDA granted fast-track, limited approval on April 30, allowing expanded access for eligible patients. Revolution Medicines said Phase 3 data will be presented at the American Society of Clinical Oncology meeting in Chicago and expressed optimism that the results will confirm the observed survival advantage.
Criticism & Access Concerns
Experts note the drug is limited to large academic centers, raising equity concerns for patients in community hospitals. Pricing has not been disclosed; oral targeted therapies have historically cost tens of thousands of dollars per month, creating insurance and affordability barriers. Oral administration may also be problematic for patients with dysphagia or severe mucosal toxicity.
Conflicting Reports & Gaps
One source lists median overall survival as 13.2 months, another cites 13.1 months, reflecting rounding. Precise rates of severe adverse events and the drug’s final price are not uniformly reported, limiting assessment of cost-effectiveness.
Verbatim Quotes
- “For that to exceed one year is really extraordinary,” — Dr. Emil Lou, Professor of Medicine, University of Minnesota
- “For all the years that I've been treating and developing new therapies for pancreatic cancer, it's still a death sentence.” — Dr. Elizabeth Jaffee, Oncology Professor, Johns Hopkins Cancer Center
- “KRAS has been considered "undruggable" for decades, said Dr.” — Dr. Despina Siolas, Assistant Professor of Medicine, Weill Cornell
- “There's no shortage of demand for patients at all stages, at all times since their time of diagnosis, who are anxiously waiting to have it available,” — Dr. Emil Lou
What's Next
Full Phase 3 results will be presented at the American Society of Clinical Oncology meeting in Chicago. Researchers plan to test daraxonrasib earlier in the treatment pathway and with immunotherapy or surgery, aiming to improve survival and quality of life for pancreatic cancer patients.
